Engert A, Schiller P, Josting A et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21: 3601-3608, 2003
Straus DJ, Portilock CS, Qin J et al: Results of a prospective randomized clinical trial of doxorubi-cin, bleomycin, vinblastine and dacarbazine (ABVD) followed by radiation therapy (RT) ver-sus ABVD alone for stage I, II, and IIIA nonbulky Hodgkin’s disease. Blood 104: 3483-3489, 2004
Canellos GP, Anderson JR, Propert KJ et al: Che-motherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-1484, 1992
Diehl V, Franklin J, Pfreundschuh M et al: Stan-dard and increased-dose BEACOPP chemother-apy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348: 2386-2395, 2003
Czuczman MS, Grillo-Lopez AJ, White CA et al: Treatment of patients with low-grade B-cell lym-phoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268-276, 1999